Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET: IV Ganaxolone in Established Status Epilepticus
NCT05757544Phase 2Withdrawn
- Sponsor
- Marinus Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Feb 2026
- Modality
- Allosteric Modulators
01
Overview
A Phase 2 trial of ganaxolone in status epilepticus (SE), sponsored by Marinus Pharmaceuticals. Planned start Apr 2023; status: withdrawn.
02
Drugs
ganaxolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT05757544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05757544.